Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
- PMID: 16913714
- DOI: 10.1021/jm060561m
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
Abstract
Structure-based design and synthesis of novel HIV protease inhibitors are described. The inhibitors are designed specifically to interact with the backbone of HIV protease active site to combat drug resistance. Inhibitor 3 has exhibited exceedingly potent enzyme inhibitory and antiviral potency. Furthermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a variety of multi-PI-resistant clinical strains. The inhibitors incorporated a stereochemically defined 5-hexahydrocyclopenta[b]furanyl urethane as the P2-ligand into the (R)-(hydroxyethylamino)sulfonamide isostere. Optically active (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[b]furan was prepared by an enzymatic asymmetrization of meso-diacetate with acetyl cholinesterase, radical cyclization, and Lewis acid-catalyzed anomeric reduction as the key steps. A protein-ligand X-ray crystal structure of inhibitor 3-bound HIV-1 protease (1.35 A resolution) revealed extensive interactions in the HIV protease active site including strong hydrogen bonding interactions with the backbone. This design strategy may lead to novel inhibitors that can combat drug resistance.
Similar articles
-
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.Acc Chem Res. 2008 Jan;41(1):78-86. doi: 10.1021/ar7001232. Epub 2007 Aug 28. Acc Chem Res. 2008. PMID: 17722874 Review.
-
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.J Med Chem. 2005 May 19;48(10):3576-85. doi: 10.1021/jm050019i. J Med Chem. 2005. PMID: 15887965
-
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.Org Biomol Chem. 2008 Oct 21;6(20):3703-13. doi: 10.1039/b809178a. Epub 2008 Aug 11. Org Biomol Chem. 2008. PMID: 18843400 Free PMC article.
-
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.AIDS Rev. 2008 Jul-Sep;10(3):131-42. AIDS Rev. 2008. PMID: 18820715 Free PMC article. Review.
-
Enamino-oxindole HIV protease inhibitors.Bioorg Med Chem Lett. 2012 Aug 1;22(15):5078-83. doi: 10.1016/j.bmcl.2012.05.120. Epub 2012 Jun 7. Bioorg Med Chem Lett. 2012. PMID: 22749283
Cited by
-
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.J Med Chem. 2009 Apr 23;52(8):2163-76. doi: 10.1021/jm900064c. J Med Chem. 2009. PMID: 19323561 Free PMC article. Review. No abstract available.
-
Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.Drug Discov Today. 2012 Oct;17(19-20):1121-6. doi: 10.1016/j.drudis.2012.06.018. Epub 2012 Jul 10. Drug Discov Today. 2012. PMID: 22789991 Free PMC article. Review.
-
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.Chem Commun (Camb). 2022 Oct 20;58(84):11762-11782. doi: 10.1039/d2cc04541a. Chem Commun (Camb). 2022. PMID: 36200462 Free PMC article. Review.
-
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.Viruses. 2023 Aug 28;15(9):1826. doi: 10.3390/v15091826. Viruses. 2023. PMID: 37766233 Free PMC article. Review.
-
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.J Med Chem. 2011 Aug 25;54(16):5890-901. doi: 10.1021/jm200649p. Epub 2011 Jul 29. J Med Chem. 2011. PMID: 21800876 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials
Miscellaneous
